Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Coya Therapeutics, Inc. (COYA)

Coya Therapeutics to open ALS extension in November 2026; FTD trial delayed to 2027

Mixed Impact 3 of 5 other Written later

Coya Therapeutics plans to start an open-label extension of its Phase 2/3 ALSTARS trial of COYA 302 in ALS in November 2026, in response to requests from investigators and participants. To prioritize the ALS program, the company now expects its Phase 2 trial of COYA 302 in frontotemporal dementia to start in 2027 rather than the second half of 2026, while its cash runway guidance is unchanged.

Key points

  • Open-label extension expected to begin in November 2026, as the first cohort completes the 48-week treatment period
  • Phase 2 trial in frontotemporal dementia now expected in 2027, previously anticipated in the second half of 2026
  • Cash resources expected to fund operations into the second half of 2027, beyond the anticipated ALSTARS topline data readout
  • ALSTARS trial to randomize approximately 120 subjects; primary endpoint is change in ALSFRS-R total score at Week 24 versus placebo

The filing

CompanyCoya Therapeutics, Inc. (COYA)
Form8-K, current report
Filed with the SECOct 14, 2026, 8:30 AM ET
Accession number0001193125-26-421066

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.